950998-61-5

Upstream product

• 1236199-90-8 C₁₅H₂₀BrN₃O₇ 
• 7143-01-3 Methanesulfonic anhydride 
• 87363-66-4 tert-butyl 2-chloro-3,5-dinitrobenzoate 
• 950998-59-1 tert-butyl 2-(bis(2-hydroxyethyl)amino)-3,5-dinitrobenzoate 
• 950998-60-4 tert-butyl 2-(bis(2-(methylsulfonyloxy)ethyl)amino)-3,5-dinitrobenzoate 

Downstream Products

• 950998-62-6 2-((2-bromoethyl)-(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-dinitrobenzoic acid 
• 1236199-61-3 C₁₉H₂₈BrN₅O₁₀S 
• 1011708-22-7 methanesulfonic acid 2-[(2-chlorocarbonyl-4,6-dinitro-phenyl)-(2-chloro-ethyl)-amino]-ethyl ester 

Relevant academic research and scientific papers

HYDROXAMIC ACID DERIVATIVES

The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

Synthesis of 3H- and 2H4-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2- (phosphonooxy)ethyl)amino)carbonyl)anilino)ethyl methanesulfonate (PR-104)

3H- and 2H4-versions of the hypoxia-activated pre-prodrug PR-104 [2-[(2-bromoethyl)-2,4-dinitro-6-[[[2- (phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate], labelled in the ethylcarboxamide side chain, have